FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Histogen's Free Cash Flow for the
three
months ended in Sep. 2023 was $-2.69 Mil. Histogen's Revenue for the
three
months ended in Sep. 2023 was $0.01 Mil. Therefore, Histogen's FCF Margin % for the quarter that ended in Sep. 2023 was -53,780.00%.
The historical rank and industry rank for Histogen's FCF Margin % or its related term are showing as below:
HSTO'
s FCF Margin % Range Over the Past 10 Years
Min: -53026.32 Med: -425.23 Max: -12.77
Current: -53026.32
During the past 4 years, the highest FCF Margin % of Histogen was -12.77%. The lowest was -53026.32%. And the median was -425.23%.
HSTO's FCF Margin % is ranked worse than 96.71% of 1034
companies
in the Biotechnology industry
Industry Median: -148.935
vs HSTO: -53026.32
Histogen FCF Margin % Historical Data
The historical data trend for Histogen's FCF Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Histogen's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Histogen's FCF Margin % Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Histogen's FCF Margin % distribution charts can be found below:
* The bar in red indicates where Histogen's FCF Margin % falls into.
Histogen FCF Margin % Calculation
FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.
Histogen's FCF Margin for the fiscal year that ended in Dec. 2022 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Histogen FCF Margin % Related Terms
Thank you for viewing the detailed overview of Histogen's FCF Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.
Histogen Inc is a clinical-stage therapeutics company focused on developing proprietary hypoxia-generated growth factor technology platforms and stem cell-free biologic products as potential first-in-class restorative therapeutics that ignite the body's natural process to repair and maintain healthy biological function. Under its biologics technology platform, the product candidates in development are HST-003, a treatment for joint cartilage repair, and HST-004, a treatment for spinal disc repair. It also has a pipeline of clinical and preclinical small molecule pan-caspase and caspase selective inhibitors focused on treatments for infectious and inflammatory diseases that the company intends to develop.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
HSTO has been successfully added to your 